Skin

argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia

Retrieved on: 
Tuesday, March 26, 2024
Diagnosis, Blood pressure, Efgartigimod alfa, System, Urination, Urinary tract infection, MHLW, Chest pain, Rituximab, Allergy, Disease, Infection, Risk, Headache, Patient, Sore throat, IWG, History, ITP, Chills, Quality of life, Cough, Euronext, Rash, Respiratory tract infection, Splenectomy, Medicine, Skin, Fever, Antibody, Wheeze, Back pain, Shivering, Safety, Pain, Fatigue, Phlegm, Swelling, Food, Autoimmune disease, Nursing

“argenx is on a mission to deliver transformative medicines for people living with severe autoimmune disease,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.

Key Points: 
  • “argenx is on a mission to deliver transformative medicines for people living with severe autoimmune disease,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.
  • By reducing circulating autoantibodies, VYVGART is uniquely designed to serve as a precision intervention that targets the underlying disease biology of ITP.
  • ADVANCE successfully met its primary endpoint, demonstrating that a higher proportion of chronic ITP patients receiving VYVGART achieved a sustained platelet count response compared to placebo.
  • Do not use VYVGART if you have a serious allergy to efgartigimod alfa or any of the other ingredients in VYVGART.

Torani Launches Dragon Fruit Syrup: A Vibrant, Subtly Sweet & Easy-to-Mix Flavor

Retrieved on: 
Tuesday, April 9, 2024
Retail, Restaurant, Bar, Food, Beverage, Consumer, Energy, Target, Partnership, Coffee, Light, Tourism, Skin, Generation Z, Fruit, Traction, Multimedia, Soft drink

Torani , a leader in the flavor industry for 99 years, today announced the newest addition to its portfolio of more than 150 syrups and sauces: Torani Dragon Fruit Syrup .

Key Points: 
  • Torani , a leader in the flavor industry for 99 years, today announced the newest addition to its portfolio of more than 150 syrups and sauces: Torani Dragon Fruit Syrup .
  • View the full release here: https://www.businesswire.com/news/home/20240409166521/en/
    Torani today announced the newest addition to its portfolio of more than 150 syrups and sauces: Torani Dragon Fruit Syrup.
  • Dragon fruit, also known as pitaya, is a unique-looking fruit characterized by its textured bright pink or red outer skin.
  • Torani Dragon Fruit Syrup is well-suited to layer with a variety of mainstream flavors to create a new and interesting combination of tastes.

ästhetik skincare Launches Vegan, Cruelty-Free Tinted Sunscreen

Retrieved on: 
Tuesday, April 9, 2024
Fashion, Cosmetics, Online Retail, Retail, Consumer, Women, Sunburn, Hyaluronic acid, Woman, Carcinogen, SPF, Skin, Face, Science, American Academy, Skin cancer, Animal

ästhetik skincare , the Florida-based clean skincare brand founded by esthetician Alexis Pfropper, today launches its newest product – the organic tinted mineral sunscreen SPF 50 .

Key Points: 
  • ästhetik skincare , the Florida-based clean skincare brand founded by esthetician Alexis Pfropper, today launches its newest product – the organic tinted mineral sunscreen SPF 50 .
  • The organic tinted mineral sunscreen SPF 50 is packed with botanicals including jojoba oil, sea buckthorn oil, hyaluronic acid and more so your skin looks glowy and healthy every time you put it on.”
    The organic tinted mineral sunscreen SPF 50 is suitable for all skin types.
  • ästhetik skincare is a Florida-based brand created by 30 under 30 sensation Alexis Pfropper, a skilled esthetician and entrepreneur.
  • ästhetik skincare products are made with plant-based ingredients and never tested on animals.

SpineX Closes Recruitment for SCONE™ Clinical Trial

Retrieved on: 
Monday, April 8, 2024
Children, Biotechnology, FDA, Health, Neurology, Health Technology, Medical Devices, Research, Consumer, Science, Clinical Trials, Cord, Brain, Cerebral palsy, Multiple sclerosis, SCIP, Patient, Stroke, Clinical trial, Urinary bladder, Trial of the century, Skin, Spinal cord, Heart, Urinary incontinence, Cauda equina syndrome, Neuromodulation, Pharmaceutical industry

SpineX Inc. has closed recruitment for its clinical trial of its proprietary SCONE™ device.

Key Points: 
  • SpineX Inc. has closed recruitment for its clinical trial of its proprietary SCONE™ device.
  • The clinical trial— Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE “CONTINENCE” Clinical Study — began in May 2022.
  • “SCONE has the power to transform the lives of millions of patients with neurogenic bladder,” says Parag Gad, SpineX co-founder & CEO.
  • SpineX anticipates beginning a multi-center pivotal trial for children with Cerebral Palsy in 2024.

Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
Monday, April 8, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Survival, A-DNA, Patient, Neoplasm, DNA, Biology, AACR, Clinical trial, Skin, Medical imaging

Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, presents preclinical and clinical pharmacodynamic data on its lead ecDNA-directed therapy (ecDTx), BBI-355, and research on ecDNA-mediated acquired resistance to chemotherapy at the American Association for Cancer Research (AACR) Annual Meeting 2024.

Key Points: 
  • Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, presents preclinical and clinical pharmacodynamic data on its lead ecDNA-directed therapy (ecDTx), BBI-355, and research on ecDNA-mediated acquired resistance to chemotherapy at the American Association for Cancer Research (AACR) Annual Meeting 2024.
  • BBI-355 is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1) being studied in the ongoing, first-in-human, Phase 1/2 POTENTIATE clinical trial in patients with oncogene amplified cancers.
  • “Extrachromosomal DNA afford unique advantages to tumors, typically rendering existing therapies ineffective and correlating with poor patient outcomes,” said Chris Hassig, Ph.D., Chief Scientific Officer of Boundless Bio.
  • BBI-355 showed substantial antitumor activity, including complete and durable regressions, in preclinical oncogene amplified models.

NOVEL 2,910 nm ULTRACLEAR® LASER FROM ACCLARO MEDICAL HITS NEW HEIGHTS AT ASLMS 2024, THE PREMIER GLOBAL CONFERENCE ON ENERGY-BASED MEDICINE AND SCIENCE

Retrieved on: 
Tuesday, April 9, 2024
Laser, Expert, Trial of the century, Master of Science, Acne, Treatment, Society, Skin, Safety, FAAD, Ageing, 3D printing

SMITHFIELD, R.I., April 9, 2024 /PRNewswire/ -- Acclaro Medical proudly announces new clinical study results on nasal contouring, acne scarring, facial resurfacing, facial and neck rejuvenation with stem cell extract and UltraClear® Laser-Coring™  will be presented at the  American Society for Laser Medicine and Surgery (ASLMS) global conference, to be held April 11-14, 2024 in Baltimore, MD. UltraClear Laser is acclaimed by aesthetic laser specialists as a game-changer in combating the signs of aging and the effects of gravity with its unrivaled cosmetic results accompanied by patient comfort, rapid healing and superb safety across all skin tones, including skin of color and tanned skin.

Key Points: 
  • UltraClear Laser is acclaimed by aesthetic laser specialists as a game-changer in combating the signs of aging and the effects of gravity with its unrivaled cosmetic results accompanied by patient comfort, rapid healing and superb safety across all skin tones, including skin of color and tanned skin.
  • "We are thrilled that UltraClear laser is taking center stage with its latest clinical study data, outstanding outcomes and innovative Laser-Coring™ techniques at this year's ASLMS meeting," said Shlomo Assa, MSc, Acclaro Medical's President and Chief Technology Officer.
  • "Our strong presence exemplifies the bold trajectory and compelling value that UltraClear brings to the future of aesthetic laser skin solutions."
  • In addition to the scientific presentations, the company will also sponsor educational events focused on these and other UltraClear laser applications.

LAURA GELLER BEAUTY UNVEILS 'OWN YOUR AGE' CAMPAIGN FEATURING LEANNE MORGAN IN HONOR OF NATIONAL MATURE WOMEN'S DAY

Retrieved on: 
Tuesday, April 9, 2024
Ageing, Address, Beauty, Woman, Pressure, AARP, Skin, Sale, Toy

NEW YORK, April 9, 2024 /PRNewswire/ -- Laura Geller Beauty, the brand known for its makeup for mature skin, is proud to announce the launch of its new campaign, 'Own Your Age,' in celebration of today's National Mature Women's Day, a day that has been created and coined by the brand.

Key Points: 
  • Laura Geller Beauty has long aimed to build a supportive and safe community for mature women in a society where aging is often associated with negative and inaccurate stereotypes.
  • In 2021, the brand created National Mature Women's Day to take place every year on April 9th to honor the beauty of aging.
  • This year, Laura Geller Beauty teamed up with comedian Leanne Morgan for their new 'Own Your Age' campaign.
  • "It's truly been an honor to team up with Laura Geller Beauty for their inspiring 'Own Your Age' campaign," notes Morgan.

Family Health & Wellness Brand, Mommy's Bliss, Launches Lactation Hydration Drink Tablets

Retrieved on: 
Tuesday, April 9, 2024
Mother, Vitamin, Tablet, Mommy's Bliss, Amazon, Disease, Milk, Electrolyte, Athlete, Skin, Water, Biotin, Mommy, Parent, Nail, Food

RICHMOND, Calif., April 9, 2024 /PRNewswire-PRWeb/ -- Mommy's Bliss, a premier wellness company that has been a leader in bringing innovative, high-quality products to families across the country, today announced the addition of Mommy's Bliss Lactation Hydration Drink Tablets to their Lactation Support Collection of products for moms.

Key Points: 
  • RICHMOND, Calif., April 9, 2024 /PRNewswire-PRWeb/ -- Mommy's Bliss , a premier wellness company that has been a leader in bringing innovative, high-quality products to families across the country, today announced the addition of Mommy's Bliss Lactation Hydration Drink Tablets to their Lactation Support Collection of products for moms.
  • I'm excited to launch a product that truly supports hydration for moms in a way specially crafted for this lactation journey.
  • Mommy's Bliss Lactation Hydration Drink Tablets are now available for $7.99 on the Mommy's Bliss website as well as through Amazon and Target .
  • For more information about the Lactation Hydration Drink Tablets and other Mommy's Bliss products, visit http://www.mommysbliss.com .

Carhartt Force Sun Defender™ Series Enhances UV Protection, Outworks the Heat

Retrieved on: 
Tuesday, April 9, 2024
Workforce, Carhartt, Element, Health, UV, Workplace, UPF, Skin, Safety, Cosmetics

DEARBORN, Mich., April 9, 2024 /PRNewswire/ -- To help all hardworking people stay cool, fight sweat and stay protected from the sun's harmful UV rays, Carhartt, America's premium workwear brand since 1889, has launched the Force Sun DefenderTM series – its lightest performance gear solution to battle the heat and sun.

Key Points: 
  • The Force Sun DefenderTM line combines the workwear brand's trusted durability with UV protection tough enough to withstand tasks ranging from the jobsite to the great outdoors.
  • Built to get the job done in the sun, the series is engineered to deliver UPF 50+ sun protection and block 98% of harmful UV rays from reaching the skin.
  • Additionally, each piece features Carhartt's Force® and FastDry® technologies, designed to wick away sweat, keep you cool and fight odors.
  • "At Carhartt, we pride ourselves upon serving and protecting hardworking people every day, no matter the task, condition or season," said Susan Hennike, chief brand officer at Carhartt.

SkinMedica® Empowers Clear Skin Confidence with a New, Modern Approach to Acne

Retrieved on: 
Tuesday, April 9, 2024
AbbVie, Antioxidant, MSRP, Nicotinamide, Physician, Patient, ABBV, Senior, Trial of the century, Acne, Skin, Aloe, Yale University, Salicylic acid, Cosmetics

The SkinMedica® Acne Clarifying Treatment and SkinMedica® Pore Purifying Gel Cleanser are breakthroughs in skincare, providing effective and balanced care for people with acne-prone skin.

Key Points: 
  • The SkinMedica® Acne Clarifying Treatment and SkinMedica® Pore Purifying Gel Cleanser are breakthroughs in skincare, providing effective and balanced care for people with acne-prone skin.
  • "The formulations of the new products continue the legacy of promoting skin health and addressing key patient concerns like acne."
  • In clinical studies, participants who used the SkinMedica® Acne Clarifying Treatment and Pore Purifying Gel Cleanser noticed clearer skin while reporting that the products did not dry their skin out.
  • "My patients often find themselves in a bind when choosing acne products that treat acne but don't compromise the skin barrier.